Gene therapy of renal cancer using recombinant adeno-associated virus encoding human endostatin

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Renal cell carcinoma (RCC) exhibits significant angiogenesis, contributing to tumor growth and relapse.
• Current therapies struggle to completely eradicate established kidney cancer, necessitating novel treatment strategies.

Purpose of the Study:

• To develop and evaluate a recombinant adeno-associated virus (rAAV) vector carrying the human endostatin gene for potential renal cancer gene therapy.
• To assess the anti-angiogenesis and antitumor efficacy of rAAV-Endostatin in preclinical RCC models.
• To investigate the safety profile of rAAV-Endostatin in vivo.

Main Methods:

• Establishment of prophylactic and therapeutic RCC mouse models via subcutaneous inoculation of RCC cells.
• Administration of rAAV-Endostatin through intra-muscular or intra-tumor injections.
• Evaluation of tumor growth kinetics (volume, weight) and assessment of microvessel density (MVD) to quantify anti-angiogenesis effects.
• Toxicological examination of rAAV-Endostatin in vital organs.

Main Results:

• Intra-tumor injection of rAAV-Endostatin significantly slowed tumor growth in therapeutic models compared to control groups (rAAV-EYFP and RPMI-1640).
• Microvessel density (MVD) was significantly reduced in xenografts treated with rAAV-Endostatin, indicating a potent anti-angiogenesis effect.
• No significant toxic side effects were observed in vital organs, suggesting a favorable safety profile.

Conclusions:

• rAAV-Endostatin demonstrates significant anti-angiogenesis and antitumor activities against renal cell carcinoma in preclinical models.
• This gene therapy approach holds promise as an effective agent for treating kidney cancer.
• Further research is warranted to explore the clinical potential of rAAV-Endostatin for renal cancer patients.